Laborijuhend · Melanokortiini ja kisspeptiini analoogid
Mis on PT-141? Bremelanotiidi (melanokortiini peptiidi) uurimistöö ülevaade
What is PT-141? It is bremelanotide, a cyclic heptapeptide melanocortin receptor agonist that shares the full ring of Melanotan II but ends in a free carboxylic acid instead of an amide. This guide covers its structure, how it differs from Melanotan II, its receptor profile and its regulatory position as the active ingredient of an FDA-approved medicine.
Peamised järeldused
- PT-141 (bremelanotide) is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, formula C50H68N14O10, molecular weight 1025.2 g/mol, CAS 189691-06-3.
- It differs from Melanotan II only at the C-terminus: a free carboxylic acid in PT-141 and an amide in Melanotan II.
- It is not receptor-selective; pharmacology across the melanocortin receptors is characterised, with MC4R central to hypothalamic research.
- Bremelanotide was granted FDA approval on 21 June 2019 as a prescription drug product; research-grade PT-141 is a different, unapproved reagent.
Mis on PT-141?
So, what is PT-141? PT-141 is the research name for bremelanotide, a synthetic cyclic heptapeptide analogue of α-MSH. The FDA label describes it as a cyclic heptapeptide with a free acid at the carboxyl terminus and an acetylated amino group at the amino terminus, Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys-OH) (FDA label). PubChem classes it as a melanocortin receptor agonist (PubChem).
Ainult teadusuuringuteks. Käesolev ülevaade võtab kokku avaldatud laboratoorsed ja loomkatsed. Baltic Peptides tarnib seda ühendit kvalifitseeritud teadlaste poolt läbiviidavateks in vitro ja prekliinilisteks uuringuteks; see ei ole ravim ega ole mõeldud kasutamiseks inimestel ega loomadel.
Keemiline struktuur ja tehnilised andmed
| Kinnisvara | Väärtus |
|---|---|
| Jada | Ac-Nle-tsüklo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Ring | Lactam between the Asp and Lys side chains |
| Molekulivalem | C50H68N14O10 |
| Molekulmass | 1025.2 g/mol (free base) |
| CAS-number | 189691-06-3 |
| PubChemi CID-number | 9941379 |
The formula, mass and CAS number match the PubChem record and the FDA review documents. The lactam ring is an amide between two side chains, not a disulfide. The free C-terminal acid is the only difference from Melanotan II, which has an amide and therefore a mass of 1024.2 g/mol, one dalton lower.
Avastamise ja uurimistöö ajalugu
PT-141 grew out of α-MSH analogue work at the University of Arizona that produced Melanotan II. A 2000 review by Wessells and colleagues discusses melanocortin receptor agonists, penile erection and sexual motivation, and describes their experience with Melanotan II in human subjects. Bremelanotide was later developed commercially by Palatin Technologies, according to the supplier product page.
The FDA granted approval to a bremelanotide injection product, Vyleesi, on 21 June 2019 (PubChem, citing DrugBank). LiverTox states that it was approved for use in the United States in 2019 for premenopausal women with hypoactive sexual desire disorder.
Mechanism: melanocortin receptor agonism
Retseptoriprofiil
PT-141 is not receptor-selective. Published pharmacology shows agonist activity at MC1R, MC3R, MC4R and MC5R, which are Gs-coupled receptors whose activation raises cAMP. Research interest centres on the centrally expressed MC4R and MC3R, while MC1R activity is associated with pigmentary effects.
Interpreting the pathway
Because several receptors are activated, a single endpoint cannot be assigned to one receptor without selective antagonists or genetic models. The clinical mechanism of the approved product is not described here beyond what the regulatory documents state.
Peamised uurimisvaldkonnad
- Melanocortin receptor pharmacology: binding and functional assays across MC1R to MC5R, compared with α-MSH and Melanotan II.
- Central melanocortin pathways: hypothalamic MC4R and MC3R signalling in preclinical models.
- Pigmentation biology: MC1R signalling in melanocytes.
- Energy homeostasis: MC4R as a regulator of appetite and energy balance.
Mida avaldatud uuringud tegelikult näitavad
| Tõendite liik | Millest teatatakse |
|---|---|
| Keemilised faktid | Sequence, formula, mass and CAS number are in FDA documents and PubChem. |
| Receptor pharmacology | Agonism at MC1R, MC3R, MC4R and MC5R without receptor selectivity. |
| Regulatiivne | FDA approval on 21 June 2019 for a specific prescription product; not described here as applying to research-grade material. |
| Kinnitamata | Receptor-specific attribution of effects, and any effect of research-grade material outside experimental settings. |
The approval concerns a defined pharmaceutical product with its own formulation, labelling and clinical programme. It does not make research-grade PT-141 a medicine.
Teaduslikud piirangud ja lahtised küsimused
- Non-selective receptor activation makes mechanistic attribution difficult.
- The FDA approval concerns one pharmaceutical product and indication, and should not be generalised to research-grade material.
- Bremelanotide is not authorised as a medicinal product in the EU, according to the supplier product page.
- Comparisons with Melanotan II depend on small structural differences that are not fully characterised in every receptor system.
Analüütilised ja laboratoorsed aspektid
Mass spectrometry should show the cyclic peptide near 1025.2 Da. The free acid distinguishes it from Melanotan II (1024.2 Da), so the two are separable by mass; they are also separable by HPLC. Tryptophan and histidine are oxidation-sensitive, and a lactam ring is not affected by reducing agents. HPLC should also resolve the D-Phe diastereomer, which has the same mass.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the PT-141 product page.
Allikad ja täiendav kirjandus
- US FDA label for Vyleesi (bremelanotide), structure and formula. FDA label data
- FDA review documents, NDA 210557 (bremelanotide structure, CAS 189691-06-3, molecular weight 1025.182). FDA
- Bremelanotide, LiverTox, NCBI Bookshelf. NCBI
- Wessells H. et al. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation. PubMed · PubChem: Bremelanotide
Kõik „ Baltic Peptides ” tooted on mõeldud kasutamiseks üksnes laboratoorsetes uuringutes. Need ei ole ravimid, toidulisandid ega toiduained ning neid ei tohi kasutada inimeste ega loomade puhul. Käesolev artikkel võtab kokku avaldatud uuringud üksnes hariduslikel eesmärkidel ega kirjeldada nende kasutamist inimeste puhul.
KKK
Korduma kippuvad küsimused
Mis on PT-141?
What is the molecular weight and CAS number of PT-141?
How is PT-141 different from Melanotan II?
Kas PT-141 on MC4R-i suhtes selektiivne?
Kas PT-141 on heakskiidetud ravim?
What does the lactam ring in PT-141 do?
How do you tell PT-141 from Melanotan II analytically?
Loe edasi
Soovitatav lugemine
PT-141
Current batches, formats and the COA for PT-141.
Mis on Melanotan II?
The amide analogue with the same cyclic backbone.
Mis on kisspeptiin-10?
A different hypothalamic peptide system studied alongside melanocortins.
Research-grade PT-141, tested before it ships
Iga EList väljasaadetud partii kohta on esitatud sõltumatu laboratooriumi HPLC ja massispektromeetria tulemused.
